A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cells

Ilgen Mender, Sergei Gryaznov, Jerry W. Shay

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Although telomerase is an almost universal target for cancer therapy, there has been no effective telomerase targeted inhibitor that has progressed to late stage human clinical trials. Recently, we reported that a telomerase-mediated telomere-disrupting compound, 6-thio-2'-deoxyguanosine (6-thio-dG), was very effective at targeting telomerase positive cancer cells while sparing telomerase silent normal cells. 6-thio-dG, a nucleoside analogue of the already-approved drug 6-thioguanine, is incorporated into telomeres by telomerase, resulting in disruption of the telomere-protecting shelterin complex. This disruption leads to Telomere dysfunction-Induced Foci (TIFs) formation and rapid cell death for the vast majority of cancer cells. Since most chemotherapies eventually fail due to drug acquired resistance, novel drugs such as 6-thio-dG, as a single first line agent or in the maintenance setting, may represent an effective new treatment for cancer patients.

Original languageEnglish (US)
Pages (from-to)693-695
Number of pages3
JournalOncoscience
Volume2
Issue number8
DOIs
StatePublished - 2015

Fingerprint

alpha-2'-deoxythioguanosine
Telomerase
Telomere
Neoplasms
Thioguanine
Nucleosides
Drug Resistance
Pharmaceutical Preparations
Cell Death
Maintenance
Clinical Trials
Drug Therapy
Therapeutics

Keywords

  • 6-thio-2'deoxyguanosine
  • 6-thioguanine
  • Cancer
  • Telomere induced foci
  • Telomere shortening

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cells. / Mender, Ilgen; Gryaznov, Sergei; Shay, Jerry W.

In: Oncoscience, Vol. 2, No. 8, 2015, p. 693-695.

Research output: Contribution to journalArticle

@article{e0c304485a9f4f7c9796d51c1e9eb833,
title = "A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cells",
abstract = "Although telomerase is an almost universal target for cancer therapy, there has been no effective telomerase targeted inhibitor that has progressed to late stage human clinical trials. Recently, we reported that a telomerase-mediated telomere-disrupting compound, 6-thio-2'-deoxyguanosine (6-thio-dG), was very effective at targeting telomerase positive cancer cells while sparing telomerase silent normal cells. 6-thio-dG, a nucleoside analogue of the already-approved drug 6-thioguanine, is incorporated into telomeres by telomerase, resulting in disruption of the telomere-protecting shelterin complex. This disruption leads to Telomere dysfunction-Induced Foci (TIFs) formation and rapid cell death for the vast majority of cancer cells. Since most chemotherapies eventually fail due to drug acquired resistance, novel drugs such as 6-thio-dG, as a single first line agent or in the maintenance setting, may represent an effective new treatment for cancer patients.",
keywords = "6-thio-2'deoxyguanosine, 6-thioguanine, Cancer, Telomere induced foci, Telomere shortening",
author = "Ilgen Mender and Sergei Gryaznov and Shay, {Jerry W.}",
year = "2015",
doi = "10.18632/oncoscience.213",
language = "English (US)",
volume = "2",
pages = "693--695",
journal = "Oncoscience",
issn = "2331-4737",
publisher = "Impact Journals",
number = "8",

}

TY - JOUR

T1 - A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cells

AU - Mender, Ilgen

AU - Gryaznov, Sergei

AU - Shay, Jerry W.

PY - 2015

Y1 - 2015

N2 - Although telomerase is an almost universal target for cancer therapy, there has been no effective telomerase targeted inhibitor that has progressed to late stage human clinical trials. Recently, we reported that a telomerase-mediated telomere-disrupting compound, 6-thio-2'-deoxyguanosine (6-thio-dG), was very effective at targeting telomerase positive cancer cells while sparing telomerase silent normal cells. 6-thio-dG, a nucleoside analogue of the already-approved drug 6-thioguanine, is incorporated into telomeres by telomerase, resulting in disruption of the telomere-protecting shelterin complex. This disruption leads to Telomere dysfunction-Induced Foci (TIFs) formation and rapid cell death for the vast majority of cancer cells. Since most chemotherapies eventually fail due to drug acquired resistance, novel drugs such as 6-thio-dG, as a single first line agent or in the maintenance setting, may represent an effective new treatment for cancer patients.

AB - Although telomerase is an almost universal target for cancer therapy, there has been no effective telomerase targeted inhibitor that has progressed to late stage human clinical trials. Recently, we reported that a telomerase-mediated telomere-disrupting compound, 6-thio-2'-deoxyguanosine (6-thio-dG), was very effective at targeting telomerase positive cancer cells while sparing telomerase silent normal cells. 6-thio-dG, a nucleoside analogue of the already-approved drug 6-thioguanine, is incorporated into telomeres by telomerase, resulting in disruption of the telomere-protecting shelterin complex. This disruption leads to Telomere dysfunction-Induced Foci (TIFs) formation and rapid cell death for the vast majority of cancer cells. Since most chemotherapies eventually fail due to drug acquired resistance, novel drugs such as 6-thio-dG, as a single first line agent or in the maintenance setting, may represent an effective new treatment for cancer patients.

KW - 6-thio-2'deoxyguanosine

KW - 6-thioguanine

KW - Cancer

KW - Telomere induced foci

KW - Telomere shortening

UR - http://www.scopus.com/inward/record.url?scp=84959261141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959261141&partnerID=8YFLogxK

U2 - 10.18632/oncoscience.213

DO - 10.18632/oncoscience.213

M3 - Article

VL - 2

SP - 693

EP - 695

JO - Oncoscience

JF - Oncoscience

SN - 2331-4737

IS - 8

ER -